Efficient and Scalable Synthesis of a Novel Selective PI3Kα Inhibitor XJTU-L453

Discovered by our research group, the novel, highly selective PI3Kα inhibitor XJTU-L453 has been selected as a preclinical development candidate for the treatment of cancer. To support early preclinical studies, a cost-effective and scalable synthesis route was required. The original medicinal chemistry route, however, presented several limitations that rendered it unsuitable for large-scale production. This work describes the development of an improved synthetic process that allows robust, scale-up preparation of high-quality XJTU-L453 with excellent impurity control. The optimized route increased the overall yield to 34% from the original 14% achieved in the initial medicinal chemistry synthesis.